Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Medivation Inc    MDVN

Delayed Quote. Delayed  - 07/27 10:00:00 pm
62.55 USD   -0.14%
07/26 MEDIVATION : Announces Second Quarter 2016 Financial Results Confere..
07/13 BioMarin Pharmaceutical shares rise after possible takeover from ..
07/11 Astra weighs $10bn bid for prostate cancer drug developer
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Medivation Inc : MDVN, OXBT, PTIE and SYMM added to NASDAQ Active Stock Watch List at EPR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/23/2013 | 03:30pm CEST

New York, NY - (ACCESSWIRE) - 10/23/2013 - Equity Profile Report initiates its NASDAQ Gainers Watch List adding Medivation, Inc. (NASDAQ:MDVN), Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT), Pain Therapeutics Inc. (NASDAQ:PTIE), and Symmetricom Inc. (NASDAQ:SYMM)

Medivation, Inc. (NASDAQ:MDVN) a biopharmaceutical company that focuses on development and commercialization of novel therapies to treat serious diseases in the United States is currently up (+8.17%) on 4,286,602 shares traded after Medivation and Astellas Announced the Phase 3 PREVAIL Trial of Enzalutamide Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naive Patients With Advanced Prostate Cancer. Medivation, Inc. (NASDAQ:MDVN) is currently up (+28.65%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Medivation, Inc. (NASDAQ:MDVN)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=MDVN&SubId=AW

Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) a development stage company that engages in developing biotechnology products that deliver oxygen to target tissues in the body primarily in the United States is currently up (+30.00%) on 6,172,456 shares traded after Oxygen Biotherapeutics Signed Agreement to Acquire Phase 3, FDA Fast Track Product to Pursue Potential $600 Million Cardiovascular Market. Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) is currently up (+52.94%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=OXBT&SubId=AW

Pain Therapeutics Inc. (NASDAQ:PTIE) a biopharmaceutical company that develops novel drugs is currently up (+16.00%) on 2,154,392 shares traded after Pain Therapeutics Reported that Pfizer Elects to Continue Development of REMOXY. Pain Therapeutics Inc. (NASDAQ:PTIE) is currently up (+75.35%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Pain Therapeutics Inc. (NASDAQ:PTIE)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=PTIE&SubId=AW

Symmetricom Inc. (NASDAQ:SYMM) a company that provides timekeeping technologies, instruments, and solutions worldwide is currently up (+51.15%) on 16,220,860 shares traded after Symmetricom Reported its First Quarter Fiscal Year 2014 Financial Results. Symmetricom Inc. (NASDAQ:SYMM) is currently up (+66.13%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Symmetricom Inc. (NASDAQ:SYMM)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=SYMM&SubId=AW

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.equityprofilereport.com/

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDIVATION INC
07/26 MEDIVATION : Announces Second Quarter 2016 Financial Results Conference Call and..
07/14 MEDIVATION : Enters into Confidentiality Agreements, Including with Sanofi
07/13 BioMarin Pharmaceutical shares rise after possible takeover from Roche
07/11 Astra weighs $10bn bid for prostate cancer drug developer
07/11 PRESS : AstraZeneca Weighing USD10 Billion Offer For US's Medivation
07/09DJCorrections & Amplifications -- WSJ
07/08 Medtech's 2016 stock surge confronts second-quarter test
07/07 MEDIVATION : Glass Lewis Recommends Medivation's Stockholders Support the Compan..
07/06 MEDIVATION, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (..
07/06 MEDIVATION : in confidentiality agreements with Sanofi and others
More news
Sector news : Bio Therapeutic Drugs
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised -- Update
07/27DJAmgen Profit Rises 13%, 2016 Outlook Raised
07/27 GSK chases next biotech asthma drug with 175 million pounds J&J deal
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
07/27 Gilead Sciences' Sales Forecast Confirms Concerns
07/27 Pivotal Discontinuation Ends Tokai Misery Early
07/26 Tokai Pharma terminates late-stage study of lead product candidate in prostat..
07/25 Is Biotech Finally Ready To Move Higher?
07/19 Big Pharma eyeing cancer therapy firms to stoke growth
Advertisement
Financials ($)
Sales 2016 920 M
EBIT 2016 314 M
Net income 2016 178 M
Finance 2016 342 M
Yield 2016 -
P/E ratio 2016 62,18
P/E ratio 2017 36,23
EV / Sales 2016 10,8x
EV / Sales 2017 8,37x
Capitalization 10 297 M
More Financials
Chart MEDIVATION INC
Duration : Period :
Medivation Inc Technical Analysis Chart | MDVN | US58501N1019 | 4-Traders
Full-screen chart
Technical analysis trends MEDIVATION INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 64,8 $
Spread / Average Target 3,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David T. Hung President, Chief Executive Officer & Director
Kim D. Blickenstaff Chairman
Marion McCourt Chief Operating Officer
Jennifer Jarrett Chief Financial Officer
Mohammad Hirmand Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDIVATION INC29.40%10 297
AMGEN, INC.5.14%128 218
GILEAD SCIENCES, INC.-19.17%108 930
CELGENE CORPORATION-9.73%83 742
REGENERON PHARMACEUTIC..-23.54%43 617
VERTEX PHARMACEUTICALS..-23.70%23 748
More Results